Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. (Q37189326)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Clara Nervi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

G Zardo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

1 reference

12 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1503-1518

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548105%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2008.141

8 January 2020

exact match

0 references

cites work

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

Oncoproteins, heterochromatin silencing and microRNAs: a new link for leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

The inheritance of epigenetic defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Heterochromatin and epigenetic control of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The function of the epigenome in cell reprogramming

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Noncoding RNAs and gene silencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Defining an epigenetic code

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Chromatin dynamics and the preservation of genetic information

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone and chromatin cross-talk

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

EUKARYOTIC CYTOSINE METHYLTRANSFERASES

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

DNA methylation: the nuts and bolts of repression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Isolation and initial characterization of the mouse Dnmt3l gene.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Dnmt3L and the establishment of maternal genomic imprints.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Epigenetic therapy of cancer: past, present and future

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Comprehensive analysis of CpG islands in human chromosomes 21 and 22

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Tiggers and DNA transposon fossils in the human genome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

DNA methylation directs a time-dependent repression of transcription initiation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Genomic DNA methylation: the mark and its mediators

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Lysine acetylation and the bromodomain: a new partnership for signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone acetyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone modifications in transcriptional regulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone methylation in transcriptional control

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone methylation: recognizing the methyl mark

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Dynamic Regulation of Histone Lysine Methylation by Demethylases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Control of developmental regulators by Polycomb in human embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Core transcriptional regulatory circuitry in human embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Polycomb silencing mechanisms and the management of genomic programmes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Gene repression by Polycomb group protein complexes: a distinct complex for every occasion?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Role of histone H2A ubiquitination in Polycomb silencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Polycomb silencing blocks transcription initiation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Mechanisms of transcriptional memory

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

HP1 binds specifically to Lys26-methylated histone H1.4, whereas simultaneous Ser27 phosphorylation blocks HP1 binding

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The Polycomb group protein EZH2 directly controls DNA methylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Architecture of a polycomb nucleoprotein complex

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

An Mll-dependent Hox program drives hematopoietic progenitor expansion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MLL targets SET domain methyltransferase activity to Hox gene promoters

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Global and Hox-specific roles for the MLL1 methyltransferase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

How is pluripotency determined and maintained?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Induction of pluripotent stem cells from fibroblast cultures.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Chromatin in pluripotent embryonic stem cells and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone H1 and the dynamic regulation of chromatin function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional genome scanning and dynamic interaction networks of chromatin proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Distinctive nuclear organisation of centromeres and regions involved in pluripotency in human embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone deacetylase activity is required for embryonic stem cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Chromatin signatures of pluripotent cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

A bivalent chromatin structure marks key developmental genes in embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Myc-binding-site recognition in the human genome is determined by chromatin context

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Severe global DNA hypomethylation blocks differentiation and induces histone hyperacetylation in embryonic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Replicating by the clock

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Neural induction promotes large-scale chromatin reorganisation of the Mash1 locus.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Role of histone H3 lysine 27 methylation in X inactivation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone modification in constitutive heterochromatin versus unexpressed euchromatin in human cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Polycomb complexes repress developmental regulators in murine embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Polycomb silencers control cell fate, development and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Lineage promiscuity and plasticity in hematopoietic development

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Hematopoietic cytokines, transcription factors and lineage commitment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The journey of developing hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Disruption of differentiation in human cancer: AML shows the way.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

GATA-1 modulates the chromatin structure and activity of the chicken alpha-globin 3' enhancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Recruitment of transcription complexes to the beta-globin locus control region and transcription of hypersensitive site 3 prior to erythroid differentiation of murine embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Transcriptional control of granulocyte and monocyte development

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The transcriptional regulation of the Colony-Stimulating Factor 1 Receptor (csf1r) gene during hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

A two-step, PU.1-dependent mechanism for developmentally regulated chromatin remodeling and transcription of the c-fms gene.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

C/EBPbeta induces chromatin opening at a cell-type-specific enhancer.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Transcription factors in myeloid development: balancing differentiation with transformation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The epigenomics of cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Cancer epigenomics: DNA methylomes and histone-modification maps

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Chromatin modifying activity of leukaemia associated fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Predicting the effect of transcription therapy in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The methyl-CpG binding protein MBD1 is required for PML-RARalpha function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Recruitment of RXR by Homotetrameric RARα Fusion Proteins Is Essential for Transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

RXR is an essential component of the oncogenic PML/RARA complex in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Oncogenic transcription factors in the human acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The 8;21 translocation in leukemogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

E protein silencing by the leukemogenic AML1-ETO fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Fusion-protein truncation provides new insights into leukemogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MOZ fusion proteins in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Oncogene-induced senescence as an initial barrier in lymphoma development

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

hDOT1L links histone methylation to leukemogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Epigenetic stem cell signature in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MLL: a histone methyltransferase disrupted in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Common mechanism for oncogenic activation of MLL by forkhead family proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

MLL fusion partners AF4 and AF9 interact at subnuclear foci

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Role of the histone deacetylase complex in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Treatment of acute myelogenous leukemia with outpatient azacitidine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

DNA methylation and cancer therapy: new developments and expectations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.141

7 January 2021